Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ARDMQ
Aradigm
$0.05
$0.05
$0.02
$0.20
$764KN/A21,923 shsN/A
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
$0.18
$0.16
$1.57
$763K4.024,068 shsN/A
Cutera, Inc. stock logo
CUTR
Cutera
$0.04
-63.9%
$0.04
$0.09
$2.37
$787K1.362.54 million shs27.70 million shs
Todos Medical Ltd. stock logo
TOMDF
Todos Medical
$0.00
$0.00
$0.00
$213K0.16218,336 shsN/A
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ARDMQ
Aradigm
0.00%0.00%0.00%0.00%0.00%
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
0.00%0.00%-99.44%-99.61%-99.91%
Cutera, Inc. stock logo
CUTR
Cutera
0.00%0.00%0.00%-89.17%-98.27%
Todos Medical Ltd. stock logo
TOMDF
Todos Medical
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ARDMQ
Aradigm
N/AN/AN/AN/AN/AN/AN/AN/A
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Cutera, Inc. stock logo
CUTR
Cutera
1.4297 of 5 stars
3.30.00.00.00.61.70.6
Todos Medical Ltd. stock logo
TOMDF
Todos Medical
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ARDMQ
Aradigm
0.00
N/AN/AN/A
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
0.00
N/AN/AN/A
Cutera, Inc. stock logo
CUTR
Cutera
2.50
Moderate Buy$3.007,592.31% Upside
Todos Medical Ltd. stock logo
TOMDF
Todos Medical
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ARDMQ
Aradigm
N/AN/AN/AN/AN/AN/A
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
$80K0.00N/AN/A($2.43) per share0.00
Cutera, Inc. stock logo
CUTR
Cutera
$155.21M0.01N/AN/A($8.62) per share0.00
Todos Medical Ltd. stock logo
TOMDF
Todos Medical
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ARDMQ
Aradigm
N/AN/A0.00N/AN/AN/AN/AN/A
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
-$6.98MN/A0.00N/AN/A-8,257.70%N/A-730.22%N/A
Cutera, Inc. stock logo
CUTR
Cutera
-$162.83M-$6.58N/AN/AN/A-84.86%N/A-45.07%8/6/2025 (Estimated)
Todos Medical Ltd. stock logo
TOMDF
Todos Medical
N/AN/A0.00N/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ARDMQ
Aradigm
N/AN/AN/AN/AN/A
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/AN/AN/AN/AN/A
Cutera, Inc. stock logo
CUTR
Cutera
N/AN/AN/AN/AN/A
Todos Medical Ltd. stock logo
TOMDF
Todos Medical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ARDMQ
Aradigm
N/AN/AN/A
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/A
0.10
0.01
Cutera, Inc. stock logo
CUTR
Cutera
N/A
2.88
1.86
Todos Medical Ltd. stock logo
TOMDF
Todos Medical
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
ARDMQ
Aradigm
N/A
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
6.91%
Cutera, Inc. stock logo
CUTR
Cutera
90.70%
Todos Medical Ltd. stock logo
TOMDF
Todos Medical
N/A

Insider Ownership

CompanyInsider Ownership
ARDMQ
Aradigm
4.50%
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
4.50%
Cutera, Inc. stock logo
CUTR
Cutera
0.42%
Todos Medical Ltd. stock logo
TOMDF
Todos Medical
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
ARDMQ
Aradigm
2315.28 millionN/ANot Optionable
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
104.74 million4.53 millionNot Optionable
Cutera, Inc. stock logo
CUTR
Cutera
46020.19 million20.10 millionOptionable
Todos Medical Ltd. stock logo
TOMDF
Todos Medical
72.13 billionN/ANot Optionable

Recent News About These Companies

Todos os Golos do Dia na UEFA Champions League
Vamos Todos Morrer
Todos Medical Ltd TOMDF
Todos Medical Announces Insolvency Proceedings in Israel
TOMDF Historical Data
Todos Medical Ltd. (TOMDF)
Todos Medical Supports Long COVID Awareness Day

New MarketBeat Followers Over Time

Aradigm OTCMKTS:ARDMQ

$0.05 0.00 (0.00%)
As of 06/30/2020

Aradigm Corp. is a leading developer of advanced pulmonary drug delivery systems for the treatment of systemic conditions as well as lung diseases. Their hand-held AERx platform is being designed for the rapid and reproducible delivery of a wide range of pharmaceutical drugs and biotech compounds via the lung.

Arch Therapeutics stock logo

Arch Therapeutics OTCMKTS:ARTH

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.

Cutera stock logo

Cutera NASDAQ:CUTR

$0.04 -0.07 (-63.86%)
Closing price 03/12/2025
Extended Trading
$0.04 0.00 (0.00%)
As of 03/12/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cutera, Inc. provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform. It also offers truSculpt, a high-powered radio frequency system designed for circumferential reduction, lipolysis, and deep tissue heating and treat all skin types; Secret RF, a fractional RF microneedling device that delivers heat into the deeper layers of the skin using controlled RF energy; and Enlighten SR/III, a laser platform with a dual wavelength for multi-colored tattoo removal, and the treatment of benign pigmented lesions and acne scars. In addition, the company provides Excel HR, a hair removal solution for all skin types; xeo, a multi-application platform for the removal of unwanted hair, treatment of vascular lesions, and skin revitalization by treating discoloration, fine lines, and laxity; and Secret DUO, two dual non-ablative fractional technologies that can be used individually or in combination to target a variety of aesthetic concerns and skin conditions on all skin types with little to no downtime. Further, it offers its products through direct sales and services, and network of distributors and direct international sales. Cutera, Inc. was incorporated in 1998 and is headquartered in Brisbane, California.

Todos Medical stock logo

Todos Medical OTCMKTS:TOMDF

Todos Medical Ltd., a vitro diagnostics company, develops and commercializes blood tests for the detection of cancer and Alzheimer disease in the United States. The company develops Total Biochemical Infrared Analysis, a proprietary cancer-screening technology using peripheral blood spectroscopy analysis for examination into cancer's influence on the immune system; Lymphocyte Proliferation Test, a diagnostic blood test that determines the ability of peripheral blood lymphocytes and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle; and blood tests for the detection of neurodegenerative disorders, such as Alzheimer's disease. Its cancer screening and diagnosis products include TM-B1 and TM-B2 for breast cancer tests; and TMC blood test for the screening and diagnosis of colon cancer. The company also offers Tollovid, a 3CL protease inhibitor dietary supplement to support healthy immune function against circulating coronaviruses; and Tollovir, an antiviral treatment for Covid-19 that is in Phase 2 clinical trial. Todos Medical Ltd. has a collaboration agreement with Integrated Health LLC, as well as has agreements with various companies to develop screening tests for SARS-nCoV-2; and to distribute certain COVID-19 test kits. Todos Medical Ltd. was incorporated in 2010 and is headquartered in Tel Aviv, Israel.